We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.75 | -2.14% | 34.25 | 34.30 | 34.95 | 35.00 | 34.25 | 35.00 | 79,407 | 08:03:29 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 205.88 | 189.05M |
From Apr 2019 to Apr 2024
TIDMAPH
RNS Number : 1937S
Alliance Pharma PLC
21 June 2018
21 June 2018
Alliance Pharma plc
("Alliance" or the "Group")
Completion of Acquisition and Total Voting Rights
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that following today's admission of 37,362,638 new ordinary shares, it has completed the acquisition of the Nizoral Rights. This follows the announcements made by the Company on 19 June 2018 in relation to the Acquisition and Placing.
The Company now has a total of 514,205,522 ordinary shares in issue. The figure of 514,205,522 ordinary shares should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Capitalised terms used but not defined in this announcement have the same meanings as set out in the announcement of the Company released at 7.00 a.m. BST on 19 June 2018.
For further information: Alliance Pharma plc Tel: +44 (0) 1249 466 966 Peter Butterfield, Chief Executive Officer Andrew Franklin, Chief Financial Officer www.alliancepharma.co.uk Numis Securities Limited Tel: +44 (0) 20 7260 1000 Nominated Adviser: Michael Meade / Freddie Barnfield / Freddie Naylor-Leyland Corporate Broking: James Black Investec Bank plc Tel: +44 (0) 20 7597 5970 Corporate Finance: Daniel Adams Corporate Broking: Patrick Robb / David Herring Buchanan Tel: +44 (0) 20 7466 5000 Mark Court / Sophie Wills / Gemma Mostyn-Owen alliancepharma@buchanan.uk.com
Notes to editors
Alliance Pharma plc is an international specialty pharmaceutical company.
Headquartered in Chippenham, UK, Alliance commenced trading in 1998 and has been listed on AIM since 2003. Alliance has a strong track record of acquiring established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. It has sales in more than 100 countries either directly via its affiliates or through its selected network of distributor partners. Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ACQSESFIFFASEFM
(END) Dow Jones Newswires
June 21, 2018 11:13 ET (15:13 GMT)
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
